90,210 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 90,210 shares of the biotechnology company’s stock, valued at approximately $902,000.

Other institutional investors also recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in shares of BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in BioCryst Pharmaceuticals by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in BioCryst Pharmaceuticals by 49.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after purchasing an additional 640,704 shares during the last quarter. Caxton Associates LLP bought a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in BioCryst Pharmaceuticals by 11.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after purchasing an additional 47,355 shares during the period. 85.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BCRX. Royal Bank Of Canada dropped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 target price for the company. Needham & Company LLC decreased their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Wall Street Zen raised BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Trading Down 2.4%

BCRX stock opened at $9.70 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22. The business’s 50 day moving average is $9.55 and its 200-day moving average is $8.88. The firm has a market cap of $2.48 billion, a P/E ratio of -6.47 and a beta of 0.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals’s revenue was up 33.6% on a year-over-year basis. During the same quarter last year, the company earned $0.15 EPS. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.